Search PubMed⌕ Search

Biomedical subjects

J Chojnowska-Jezierska

Publications and source records attributed to J Chojnowska-Jezierska.

At least 19 recordsLinked to original sources
PubMed2002

The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.

BACKGROUND: . The beneficial effects of statins on clinical events may involve mechanisms that modify endothelial dysfunction, plaque stability, thrombus formation, and inflammatory responses. To determine the effect of atorvastatin on blood rheology in patients with familial hypercholesterolemia (FH), we prospectively studied serum lipid concentration, red cell cholesterol content, lipid peroxidation and erythrocyte membrane fluidity. The aim of this paper was to evaluate the effects of atorvastatin therapy on the erythrocyte membrane structure and the hypolipemic efficacy in patients with FH. MATERIALS, METHODS AND SUBJECTS STUDIED:. The study involved 31 patients with FH and 20 healthy individuals as a control group. The program lasted 20 weeks. For the first 8 weeks, the patients were on a hypolipemic diet only and for the subsequent 12 weeks, alongside the diet they were given 10 mg atorvastatin per day. Laboratory tests were carried out before and after 4 weeks and 12 weeks of the pharmacological treatment. Erythrocyte membrane fluidity was determined using the spin labeled method. The peroxidation of lipids was measured in whole erythrocytes as well as in erythrocyte plasma membranes by means of the thiobarbituric acid technique. RESULTS: . Treatment with atorvastatin reduced serum total cholesterol concentration from 310+/-29 mg/dl in a basal situation to 203+/-34 mg/dl ( P<0.001) at the end of the treatment and low-density lipoprotein (LDL) cholesterol concentration from 225+/-30 mg/dl to 126+/-30 mg/dl ( P<0.001), respectively. The changes observed in the plasma lipids correlate with a significant decrease in erythrocyte membrane cholesterol, from 2.24+/-1.69 to 1.17+/-0.75 mg/mg protein ( P<0.001) after 12 weeks of treatment. The lipid peroxidation in membranes of erythrocytes was lowered from the basal value 0.171+/-0.097 to 0.100+/-0.024 mmol/mg protein ( P<0.05) after 4 weeks of treatment and to 0.057+/-0.020 mmol/mg protein ( P<0.001) after 12 weeks of treatment, and in total erythrocytes from 4.78+/-1.49 to 3.99+/-1.39 mmol/g Hb ( P<0.02) and 2.43+/-0.87 mmol/g Hb ( P<0.001), respectively. The membrane fluidity was estimated by means of parameter S at the depth of the fifth carbon atom. Atorvastatin in hypercholesterolemic erythrocytes enhances the fluidity of the superficial layer from 0.758+/-0.009 up to the values observed in the control group 0.744+/-0.009 ( P<0.001). There is no impact on the microviscosity of the hydrophobic core observed. CONCLUSION: . Our findings suggest that the atorvastatin therapy reverses the alteration of erythrocyte plasma membrane properties. It may improve blood rheology in patients with FH. This improvement in blood properties may contribute to the well-known beneficial effects of atorvastatin on cardiovascular risk in patients with severe hyperlipidemia and atherosclerotic vascular disease.

Adult↗
PubMed2000

[Undesirable drug interactions of hypolipemic drugs].

The paper presents undesirable hypolipaemic drug interactions. Statins interactions are mainly connected with their hepatic metabolism by cytochrome P-450 isoenzymes. Most statins are metabolised by the CYP3A4 izoenzyme (lovastatin, simvastatin, atorvastatin, cerivastatin). The CYP3A4 isoenzyme is also responsible for the metabolism of wide range of drugs. The use of the combination of statins and some other drugs metabolised by, or affecting the activity of this same enzyme, may increase the risk of myopathy and rhabdomyolysis. It has been emphasized that pravastatin--and fluvastatin interactions are rarer and weaker than interactions of other statins. The most common appearance of interactions of hypolipaemic drugs, also other than statins have been presented.

Cytochrome P-450 Enzyme System↗
PubMed1998

Bisoprolol in the treatment of hypertension in the elderly.

The aim of the study was to examine the hypotensive efficacy and tolerance of bisoprolol in elderly patients. Sixty patients (40 <65 years and 20 >65 years) with mild-to-moderate essential hypertension (diastolic blood pressure (DBP) between 95 and 109 mm Hg) were included in the study. After a 2-week run-in period on placebo, patients began bisoprolol therapy (5 mg/d) for 12 weeks. After 4 weeks the dose was increased to 10 mg/d in those with a DBP > or =95 mm Hg. Additionally, in 10 patients over 65 years old, 24-h ambulatory BP monitoring (ABPM) was performed, after placebo and after bisoprolol (5 mg) administration. The hypotensive efficacy of bisoprolol in the elderly and younger patients was similar. Before and after treatment the mean difference of systolic BP (SBP) was 19.6 +/- 12.5 mm Hg and DBP 9.6 +/- 6.2 mm Hg in the younger patients and 16.1 +/- 13.6 mmHg and 9.5 +/- 6.0 mmHg in the elderly patients. Bisoprolol produced a similar reduction in heart rate (23.1% vs 17.1%) in the estimated groups. The tolerance of bisoprolol was good in both groups. There were no significant differences in adverse drug reactions between the groups.

Adult↗
PubMed1998

Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.

The paper is aimed at evaluation of the efficacy and safety of one-year therapy with slow-release nicotinic acid (NA-SR). The study involved a group of 30 patients with hyperlipidemia of type II. The concentration of nicotinic acid in serum was determined using capillary electrophoresis. After the placebo period (2 months), NA-SR was applied at the dose of 1.5 g/d (2 months), and subsequently 2-3 g/d (10 months), on average 2.13 g/d. During the treatment with 2.0 g/d dose, the steady-state concentration of NA in serum was within a range of 2.7-4.9 microg/ml and with 3.0 g/d of 6.17-7.75 microg/ml. These doses of the drug were tolerated well and advantageously modified the serum lipids.

Adult↗
PubMed1998

[Effect of one-year treatment with low simvastatin doses on lipids and Lp(a) in patients with significant hypercholesterolemia].

The aim of study was to evaluate efficacy and safety of one-year therapy with simvastatin in relative low doses (5-20 mg/d). The examination was performed in the group of 55 patients with significant hypercholesterolemia (Fredrickson's type II). During one-year treatment with simvastatin there were observed the mean decrease of total cholesterol (TC) by 26%, LDL-C by 37%, and LDL-C/HDL-C rate by 38%. The normalization of cholesterolemia (TC < 200 and LDL-C < 130 mg/dL) was observed in 53% of patients (group A-75%, and group B-39%). Effective doses of simvastatin varied from 5 to 20 mg/d. Lp(a) decreased statistically significantly only in the group of patients with extensively elevated Lp(a): from 121.1 +/- 46.2 mg/dL before the treatment to 95.3 +/- 31.3 mg/dL after them. Hepatotoxic effects were not observed and antipyrine kinetics did not change during one-year treatment with simvastatin.

Adult↗
PubMed1997

[Prolonged treatment with slow release nicotinic acid in patients with type II hyperlipidemia].

The aim of the study was to compare efficacy and safety of one-year therapy with slow-release nicotinic acid (KN-SR) and with ordinary form of the acid (KN). The examination was performed in the group of 136 patients with hyperlipidemia-type II. KN-SR had satisfactory effectiveness and was much better tolerated than KN. During one-year treatment with KN-SR there were observed the decrease of total cholesterol (TC) by 18%, LDL-C by 22%, triglycerides by 36%, Lp(a) by 56%, and the increase of HDL-C by 12%. The percentage of skin unwanted signs differed significantly between KN-group (90.2%) and KN-SR group (24%). Hepatotoxic effects were not observed and antipyrine kinetics did not change during one-year treatment with slow-release nicotinic acid.

Adult↗
PubMed1994

[Lovastatin in the treatment of hypercholesterolemia].

In 9 clinics 177 patients (68 men and 109 women) aged 23-69 years with primary hypercholesterolemia (TC above 6.5 mmol/L) were treated with lovastatin for 12 weeks. The treatment was started with 20 mg daily. The dose was doubled every 4 weeks, if the total serum cholesterol level did not fall below 5.2 mmol/L. For 4 weeks before treatment with lovastatin all patients received placebo. After the first 4 weeks of therapy the mean TC level decreased significantly (from 8.09 mmol/L to 6.54 mmol/L) by 18.5%. In comparison with the results after placebo (the starting value), after the 8 weeks of the therapy the TC level reduction reached 22.4% and after 12 weeks 23.5%. The mean LDL cholesterol decreased by 26.1%, 30.8% and 32.9% after 4.8 and 12 weeks of lovastatin treatment respectively. An increase in HDL cholesterol by 5.9%, 6.0% and 7.6% and decrease in triglyceride level by 10.7%, 14.9% and 14.0% respectively was also observed. In 6 patients on lovastatin treatment symptoms of acute pancreatitis in 1 case, a cataract in 1 case and aggravation of coronary insufficiency in 4 cases were noticed. These symptoms in the light of our knowledge of the mechanism of action of the drug used and of its side effects described in other trials, may be considered of independent on lovastatin. The treatment was discontinued in 5 cases (because of gastrointestinal intolerance in 2 patients, of aggravation of coronary insufficiency in 2 patients and of pain in the right hypochondrium in 1 patient who himself decided to stop the therapy).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1993

[Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II].

Hypolipaemic effectiveness and unfavourable effects of acipimox and fenofibrate were evaluated in patients with essential hyperlipoproteinaemia type II. The studies were carried out in two groups of 30 patients each. The studied patients were treated for three months with diet, and for another three months one group received acipimox (750 mg/day), and the other group was given fenofibrate (300 mg/day). After three months of pharmacological treatment in both groups a statistically significant decrease was seen of the concentrations of total cholesterol (by 13.8% and 19.3% respectively), LDL cholesterol (by 16.3% and 22.1%). TG (by 22.7% and 28.9%). The increase of HDL cholesterol concentration (twofold increase after fenofibrate) was non-significant. Desired LDL cholesterol values were achieved in eight patients (26.7%) treated with fenofibrate and in two patients (6.6%) receiving acipimox. Both drugs were well tolerated. Unfavourable effects were slight and did not require drug withdrawal.

Adult↗
PubMed1989

[Effectiveness of diet therapy of obesity in women in the climacteric period].

Twenty-five women at the climacteric age (mean age 48.5 +/- 5.5 years) were treated for simple obesity (mean overweight 37.8%) giving them low-calorie, low-carbohydrate and low-sodium diet for 14 days. The diet was very well tolerated by the patients. The mean weight loss was 4.4 kg, with 72.7% of this loss in the first week on the diet. A considerable reduction of the activity of dopamine beta-hydroxylase were noted, indicating a decrease of the activity of the adrenergic system. At the same time the diet stimulated thyroid function, as shown by increased concentration of total thyroxine (without exceeding the normal upper range), and higher free thyroxine index. Besides that, the serum uric acid level was increased. No changes of electrolyte levels were noted. The diet was effective and well tolerated in this treatment of women in climacteric age for obesity.

Adult↗